Acumen Pharmaceuticals Inc(ABOS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.55 | Insider Own | 14.6% | Shs Outstand | 72.3M | Perf Week | -90.91% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 52.35% | Insider Trans | -0.37% | Shs Float | 61.8M | Perf Month | -89.34% |
| Enterprise Value | -0.04B | PEG | - | EPS next Q | -0.38 | Inst Own | 58.75% | Short Float | 5% | Perf Quarter | -90.51% |
| Income | -0.10B | P/S | - | EPS this Y | 24.29% | Inst Trans | 3.54% | Short Ratio | 1.43 | Perf Half Y | -91.58% |
| Sales | 0.00B | P/B | 0.45 | EPS next 5Y | 50.45% | ROA | -91.28% | Short Interest | 3.09M | Perf YTD | -89.75% |
| Book/sh | 0.48 | P/C | 0.2 | EPS past 3/5Y | -23.82% -61.49% | ROE | -162.72% | 52W High | -93.99% ($3.60) | Perf Year | -88.85% |
| Cash/sh | 1.09 | P/FCF | - | Sales past 3/5Y | - | ROIC | -256.84% | 52W Low | 9.24% ($0.20) | Perf 3Y | -90.12% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 29.92% | Gross Margin | - | Volatility(W/M) | 27.79% 13.58% | Perf 5Y | -98.53% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.27 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.89 | EPS Q/Q | 19.67% | Profit Margin | - | RSI (14) | 20.89 | Recom | 3.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.89 | Sales Q/Q | - | SMA20 | -86.94% ($1.68) | Beta | 0.44 | Target Price | $1 |
| Payout | - | Debt/Eq | 0.76 | Earnings | 2026/10/26 | SMA50 | -90.32% ($2.27) | Rel Volume | 4.01 | Prev Close | $0.23 |
| Employees | 61 | LT Debt/Eq | 0.17 | EPS/Sales Surpr. | 9.93% - | SMA200 | -91.27% ($2.52) | Avg Volume(3M) | 2.17M | Price | $0.22 |
| IPO | 2021/7/1 | Option/Short | Yes/Yes | Trades | 6721 | Volume | 8,679,180 | Change | -7.72% |
🧠 Acumen Pharmaceuticals (ABOS) is a clinical-stage biopharmaceutical company developing treatments for Alzheimer's disease. Founded by neuroscience researchers, the company focuses on developing antibody candidates that target amyloid-related pathological mechanisms and maintains an early-stage pipeline prior to commercialization.
Over the past 1 year, on the lower side
94% below its 1-year high.
Traded more than usual. That is 401% of its average volume.
ABOS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +24.3% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.5%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 58.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #478 of 597 in the industry
Based on market cap of $16M.
NEUP#476 Neuphoria Therapeutics Inc $16M PER - 
KYNB#477 Kyntra Bio Inc $16M PER 0.1 ABOS#478 Acumen Pharmaceuticals Inc $16M PER - 
PLUR#479 Pluri Inc $16M PER - 
ATYR#480 Atyr Pharma Inc $15M PER - 
FAQ
What kind of company is ABOS?
ABOS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ABOS?
The market cap of ABOS is approximately $16M, ranking 5,284 within its sector.
What is the 52-week high and low for ABOS?
ABOS has recorded a 52-week high of $3.60 and a low of $0.20.
